中危前列腺癌单纯近距离放疗与联合外照射的结局与毒性
回顾性分析902例中危前列腺癌患者,390例接受单纯近距离放疗,512例接受联合外照射放疗,中位随访91个月。联合外照射未显著改善生化控制或远处转移,但晚期毒性(尿急、血尿、排尿困难、IPSS生活质量变化)及勃起功能丧失更常见。
要点
- 联合外照射未显著改善中危前列腺癌的生化失败或远处转移。
- 联合外照射组晚期尿急、血尿、排尿困难及IPSS生活质量变化显著多于单纯近距离放疗组。
- 疗前勃起功能良好者中,联合外照射组勃起功能丧失更常见(P=0.040)。
核心结论
- 单纯近距离放疗对具有一个及多个中危特征的患者均获得同等生化控制和远处控制。
- 虽无显著获益,作者认为对多个中危特征患者加用外照射可能预防复发,应考虑使用。
研究设计与样本
- 回顾性分析前瞻性收集数据库,1990-2014年中危前列腺癌患者902例,中位随访91个月。
- 390例接受单纯近距离放疗,512例接受近距离放疗联合外照射,联合或不联合雄激素剥夺治疗。
主要发现
- 具有一个中危因素者,加用外照射对无生化失败生存或无远处转移生存无显著影响。
- 具有两个或三个中危因素者,加用外照射未改善无生化失败生存。
- 单纯近距离放疗与联合外照射的晚期毒性差异显著:尿急(P<0.001)、血尿(P<0.001)、排尿困难(P<0.001)、IPSS生活质量变化(P=0.002)。
- 疗前勃起功能良好者中,联合治疗组更频繁出现勃起功能丧失(Mount Sinai勃起功能量表,P=0.040)。
临床怎么用
- 中危前列腺癌患者行单纯近距离放疗可获得与联合外照射同等的生化和远处控制。
- 联合外照射增加晚期泌尿系统毒性和勃起功能丧失风险,选择方案时需权衡。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cancer control outcomes and long-term treatment-related morbidity of brachytherapy as well as combination brachytherapy and external beam radiation therapy (EBRT) in patients with intermediate-risk prostate cancer. MATERIALS AND METHODS: A retrospective review was conducted in a prospectively collected database of patients with intermediate-risk prostate cancer who were treated either with brachytherapy or brachytherapy and EBRT, with or without androgen deprivation therapy (ADT), in the period 1990-2014. Urinary and erectile dysfunction symptoms were measured using the International Prostate Symptom Score (IPSS), the Mount Sinai erectile function scale and the Sexual Health Inventory for Men (SHIM). Cancer control endpoints included biochemical failure and development of distant metastases. All statistical analyses were carried out using the Statistical Package for Social Science (SPSS). Survival curves were calculated using Kaplan-Meier actuarial methods and compared using log-rank tests. Cox regression multivariate analyses were used to test the effect of multiple variables on treatment outcomes. RESULTS: A total of 902 patients were identified, with a median follow-up of 91 months. Of these, 390 received brachytherapy and 512 received combination therapy with EBRT. In patients with one intermediate-risk factor, the addition of EBRT did not significantly affect freedom from biochemical failure or distant metastases. Among patients with two or three intermediate-risk factors, added EBRT did not improve freedom from biochemical failure. Significant differences in late toxicity between patients treated with brachytherapy vs combination brachytherapy and EBRT were identified including urge incontinence (P < 0.001), haematuria (P < 0.001), dysuria (P < 0.001), and change in quality-of-life IPSS (P = 0.002). These symptoms were reported by patients at any point during treatment follow-up. Analysis of patients who were potent before treatment using actuarial methods showed that patients receiving combination therapy more frequently experienced loss of potency, as measured by the Mount Sinai erectile function scale (P = 0.040). CONCLUSION: Brachytherapy monotherapy results in equal biochemical and distant control in both patients with one and more than one intermediate-risk features. While no significant benefit was shown, we believe that the addition of EBRT may prevent recurrence in patients with multiple intermediate-risk features and should be considered.
引用
- Schlussel Markovic E, Buckstein M, Stone NN, et al. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. BJU Int. 2018. PMID: 29319919. doi:10.1111/bju.14128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。